Home > Insider Trading > Filing (0001209191-23-006054)

Filing Details

Accession Number:: 0001209191-23-006054
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-02-01 20:32:14
Reporting Period:: 2023-01-30

Accepted Time:: 2023-02-01 20:32:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1435049	Chinook Therapeutics Inc.	KDNY	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1202785	Eric Dobmeier	C/O Chinook Therapeutics, Inc. 400 Fairview Ave. No., 9Th Floor Seattle WA 98109	President, Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-01-30	25,000	$0.42	296,676	No	4	M	Direct
Common Stock	Disposition	2023-01-30	25,000	$24.54	271,676	No	4	S	Direct
Common Stock	Acquisiton	2023-01-31	24,999	$0.00	296,675	No	4	M	Direct
Common Stock	Disposition	2023-01-31	7,688	$24.68	288,987	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-01-30	25,000	$0.00	25,000	$0.42
Common Stock	Stock Option (Right to Buy)	Acquisiton	2023-01-31	255,150	$0.00	255,150	$25.27
Common Stock	Restricted Stock Unit	Acquisiton	2023-01-31	64,050	$0.00	64,050	$0.00
Common Stock	Restricted Stock Unit	Disposition	2023-01-31	24,999	$0.00	24,999	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
338,555	2030-03-17	No	4	M	Direct
255,150		No	4	A	Direct
64,050		No	4	A	Direct
50,001		No	4	M	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.27 to $24.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
Restricted stock units (RSUs) convert into common stock on a one-for-one basis.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
The stock option vested as to 25% of the total shares monthly on March 6, 2021, and thereafter vests as to 1/48 of the total shares until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
The stock option vests as to 25% of the total shares on January 31, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.
The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.